The Legalised Manufacturer Registration Certificate

1. Key takeaways

The third document in company-level device registration in Iraq is the manufacturer registration certificate in the country of origin, officially legalized. The regulation itself defines no legalisation tiers and names no sealing authorities. By comparison with Section E item 2 on pharmaceutical CPPs, the most complete form of “official legalisation” in the Iraqi system can be inferred as a three-tier chain; but as of this verification pass, no provision on device-side legalisation tiers was retrieved in any officially accessible channel, and because the Ministry of Health site and official legal repositories were unreachable, the situation must not be stated as “Iraq imposes no legalisation-tier requirement on devices”. Practical estimate: no official provision was found defining the device-side legalisation tiers and authorities.

• Section D item 3 requires a manufacturer registration certificate issued in the country of origin, officially legalized, with no tiers named.
• Section E item 2, for pharmaceutical CPPs, names three authorities: Ministry of Health, Ministry of Foreign Affairs and the Iraqi embassy in the country of origin.
• Both provisions use the same wording (“legalized officially”/“officially legalized”), but only the pharmaceutical provision names three authorities.
• The Chinese counterparts are the medical device production licence (or first-class production filing certificate) and the business licence.
• Whether Iraq accepts apostille could not be confirmed from any official provision and must be confirmed case by case with the Iraqi embassy.

2. Legal basis

The requirement sits in the Drug Registration Regulations, issued by the Republic of Iraq, Ministry of Health, Technical Affairs Directorate, Registration Department, bearing no number and no publication date in the copy reviewed. The operative device provision is Section D item 3; the pharmaceutical CPP chain in Section E item 2 is comparison only.

Evidence level: [second-hand source; must not be cited as law]. The original was not obtained; the surviving text is the Pharmexcil reposted PDF (https://pharmexcil.com/uploadfile/ufiles/380351111_drug_regpdf.pdf ). Everything here is treated as derived from a second-hand repost and must be re-verified with the Registration Department.

Verbatim extracts of the provisions:

• Section D item 3: «manufacturer registration certificate in the country of origin officially legalized» — a manufacturer registration certificate from the country of origin, officially legalized.
• Section E item 2 (pharmaceuticals, for comparison): «CPP issued by the health authority of the country of origin of the manufacturer legalized officially: from Ministry of Health, Ministry of Foreign affairs and Iraqi Embassy in the country of origin of the manufacturer».
• Both use «legalized officially»/«officially legalized»; the wording is consistent within the instrument, but only the pharmaceutical provision names the three authorities.

3. Expert insights

Insight 1: the word “legalized” wears two faces in this instrument. On the device side the text stops at “officially legalized”; on the pharmaceutical side the chain is broken into three stages. Same word, different density — not an oversight but the direct expression of a scope difference: pharmaceuticals have product registration and need seal authenticity confirmed on every foreign document; devices do not, so the registration office only needs to confirm that “this manufacturer lawfully exists in its country of origin”.

Insight 2: horizontal comparison — what Chinese exporters actually hold. China has no document named “manufacturer registration certificate”; the counterparts are the business licence and the medical device production licence (production filing certificate for Class I). GRZAN uses the production licence as principal document and the business licence as companion, with a cover letter explaining the relationship — a business licence alone invites supplementary demands.

Insight 3: which route applies depends on whether Iraq accepts the simplified path. Two routes exist: Hague apostille, and consular legalisation (notarisation, home-country foreign ministry, embassy in China). GRZAN found no official provision on whether Iraq accepts apostille; the current requirements of China’s Ministry of Foreign Affairs and the Iraqi embassy must be confirmed case by case. Practical estimate: no official provision on device-side legalisation tiers.

Insight 4: falsification check — “all device documents need three-tier legalisation” is a blended reading. The claim most likely merges the pharmaceutical CPP three-tier requirement of Section E item 2 with the Section D device documents. Among the six Section D documents, only item 3 carries the word “legalized” and names no tiers; item 1 requires signature and stamp, not legalisation. The judgement is limited to the document obtained and accessible channels, not asserted as final.

Insight 5: front-load the time cost into the project plan. Three-tier legalisation involves notarisation, the foreign ministry and the embassy; a supplementary demand at any stage resets the schedule. GRZAN starts this item first, not after the other documents are ready. Practical estimate: the actual duration of the chain has no official provision behind it (no official provision found).

4. Practical recommendations

• Take the medical device production licence as principal document (production filing certificate for Class I), pair it with the business licence, and attach a cover letter explaining the relationship and the manufacturing scope.
• Confirm with the Iraqi embassy in China the accepted legalisation form and number of copies before starting notarisation, to avoid rework on outdated assumptions. Practical estimate: no official provision on device-side legalisation tiers.
• The name, address and manufacturing scope on the certificates must match the company registration form and product catalogue exactly — two addresses across three documents are the most common cause of supplementary demands in Iraqi projects.
• Keep receipts and sign-off records of the whole legalisation process; at re-registration and renewal this trail saves the cost of running the chain again.
• If the manufacturer has several sites in the same country of origin, first confirm whether the registration office receives by entity or by site; the text is silent, so confirm with the Registration Department in writing before submission.

5. Verification checklist

• □ Obtain the .gov.iq original and confirm whether Section D item 3 still reads “officially legalized”
• □ Search whether the Ministry of Health or Technical Affairs Directorate has an instruction defining device-side legalisation tiers (authorities, sequence, copies)
• □ Confirm with the Iraqi embassy in China whether apostille is accepted or full consular legalisation is required
• □ Search official sites using «شهادة تسجيل الشركة المصنعة» and «مصدقة اصولياً» for the current wording
• □ Verify that names and addresses on the production licence, business licence and company registration form are consistent
• □ Record the actual stages and durations of this legalisation round as a baseline (practical estimate; no official time-limit provision found)
• □ Re-verify whether the cited official documents have been superseded (verification baseline date: 29 October 2026)

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team prepares registration dossiers and legalisation chains, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com